Marijuana Reclassification Explained: What the Trump Administration’s Schedule 3 Move Actually Means
On April 23, 2026, the Trump administration officially moved FDA-approved marijuana products and marijuana products regulated under qualifying state medical marijuana licenses from Schedule I to Schedule III under federal law. If you’re trying to understand what that actually means — for dispensaries, patients, cannabis businesses and federal policy — this is the explainer. For […]
Trump ready to move on cannabis rescheduling (Newsletter: April 23, 2026)
VA lawmakers reject gov’s marijuana amendments; CA dispensary drive-thrus; Federal cannabis research bill; Legalization poll Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Your support makes Marijuana Moment possible… Free to read (but not free to […]
FDA’s New Hemp CBD Enforcement Move Is Encouraging, But Congress Still Needs To Enact Real Regulations (Op-Ed)
“These products have the potential to reshape how Americans approach wellness by offering accessible, plant-based alternatives that complement traditional care, but realizing that potential will require more than enforcement discretion.” By Thomas Winstanley, Edibles.com For years, the hemp-derived CBD market has operated in a paradox: federally legal, widely available and increasingly normalized—yet lacking a clear […]
A Rare South American Cannabis Power Move Is Taking Shape In Argentina
Flowers & Terps and Universal Growing are joining forces in a move that blends flower credibility, cultivation culture, infrastructure and global ambition, an uncommon kind of partnership in South America’s cannabis industry. Something unusual is happening in South American cannabis, and it starts in Argentina. Flowers & Terps, a flower-driven brand with unmatched credibility in […]
New Cannabis Group Will Help Ground Policy In Science And Patient Experience As Trump’s Rescheduling Move Advances (Op-Ed)
“Federal policy must reflect evidence and science, not dispelled myths and tired stereotypes.” By Sasha Kalcheff-Korn, National Compassionate Care Council Recent federal action initiating a review of cannabis scheduling and signaling interest in expanding cannabinoid research reflects a growing willingness to examine how federal policy aligns with emerging evidence and real-world patient experience—but it also […]
Trump’s Cannabis Rescheduling Move Alone Won’t Stabilize The Industry Without Insurance Reimbursement Reform (Op-Ed)
“A stable cannabis industry requires more than tax normalization. It requires integration into healthcare infrastructure that governs how therapeutic products are accessed, financed and sustained.” By Gennaro Luce and Matthew Myro Rothman, CannaLnx Momentum around federal cannabis reform has shifted. Following President Donald Trump’s executive order directing the rescheduling of cannabis, investors have interpreted the […]